Breast & Women's Cancer

Disease Education

Disease Education MOA Resources Clinical Trials

.atomic-select.jsAtomicSelect { display: none; }

Disease Education

Disease Education MOA Resources Clinical Trials

Reimagining Medicine for Patients With Breast Cancer

More Than Just Words

More Than Just Words is a multiyear initiative in the US to drive toward health equity in breast cancer where there is an unmet need.

Learn More

The PI3K Pathway in Cancer

The phosphoinositol 3 kinase (PI3K) pathway has been demonstrated to regulate many cellular processes, and when hyperactivated, to promote cancer. Learn more about the role of PI3K signaling in promoting the survival and proliferation of tumors.

Reimagining Medicine for Patients With Breast Cancer

Intrinsic Subtypes in HR+/HER2-

Learn more about the prognostic and predictive value of intrinsic subtypes in HR+/HER2- advanced breast cancer and the capacity of these subtypes to subtype switch.

Alpelisib Mechanism of Action in Breast Cancer

Learn more about the investigation of alpelisib and the role of PI3K pathway hyperactivation in HR+/HER2- aBC, HER2+ aBC, and TNBC.

Alpelisib Mechanism of Action in Ovarian Cancer

Learn more about the investigation of alpelisib and the potential role of the PI3K pathway in treatment-resistant ovarian cancer.

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
MOA is based on in vitro/in vivo data. Clinical benefit is unknown.

aBC = advanced breast cancer; DNA = deoxyribonucleic acid; HER2- = human epidermal growth factor receptor 2 negative; HER2+ = human epidermal growth factor receptor 2 positive; HR+ = hormone receptor positive; PI3K = phosphoinositol 3 kinase; TNBC = triple-negative breast cancer.

Breast & Ovarian Cancer Clinical Trial Swimlane

Explore Clinical Trials

Adjuvant HER2+

EPIK-B2

Trastuzamab + Pertuzumab + Alpelisib as Maintenance Therapy in PIK3CA Mutated HER2+ Advanced Breast Cancer

Advanced TNBC

EPIK-B3

Alpelisib Plus Nab-pacitaxel in Patients With Advanced Triple-Negative Breast Cancer With PIK3CA Mutation or PTEN Loss Without PIK3CA Mutation

HR+/HER2- ABC

EPIK-B4

Study of the Safety and Efficacy of Dapagliflozin + Metformin XR vs Metformin XR During Treatment With Alpelisib and Fulvestrant in Patients With HR+, HER2-, PIK3CA mutation-positive Advanced Breast Cancer

HR+/HER2- ABC

EPIK-B5

Alpelesib + Fulvestrant in Patients with HR+, HER2- Advanced Breast Cancer After Treatment with a CDK4/6 Inhibitor and an Aromatase Inhibitor

HGSOC

EPIK-O

Alpelisib + Olaparib in Platinum-Resistant or Refractory, Germline BRCA Mutation Negative High-grade Serous Ovarian Cancer

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Explore Compounds

Alpelisib (BYL719)

PI3K small-molecule inhibitor

Spartalizumab (PDR001)

PD-1–targeting monoclonal antibody

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
MOA is based on in vitro/in vivo data. Clinical benefit is unknown.

.lazy { display: none; }

Use of website is governed by the Terms of Use and Privacy Policy.

8/21 121333-1

Reimagining Medicine for Patients With Breast Cancer

More Than Just Words

The PI3K Pathway in Cancer

Reimagining Medicine for Patients With Breast Cancer

Intrinsic Subtypes in HR+/HER2-

Alpelisib Mechanism of Action in Breast Cancer

Alpelisib Mechanism of Action in Ovarian Cancer

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.MOA is based on in vitro/in vivo data. Clinical benefit is unknown.

Explore Clinical Trials

Explore Clinical Trials

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Explore Compounds

Explore Compounds

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.MOA is based on in vitro/in vivo data. Clinical benefit is unknown.

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
MOA is based on in vitro/in vivo data. Clinical benefit is unknown.

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
MOA is based on in vitro/in vivo data. Clinical benefit is unknown.